CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM133189
Első szerző:Dániel Eszter (orvos)
Cím:Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1 : results from a One-Year Study in Type 2 Diabetes / Dániel Eszter, Sztanek Ferenc, Csiha Sára, Ratku Balázs, Somodi Sándor, Paragh György, Harangi Mariann, Lőrincz Hajnalka
Dátum:2025
ISSN:1661-6596 1422-0067
Megjegyzések:The role of insulin-like growth factor-binding proteins (IGFBPs) in the regulation of carbohydrate metabolism and the development of complications is well established; however, the impact of the glucagon-like peptide-1 receptor agonist semaglutide on IGFBPs has not been previously investigated. We aimed to examine the effects of semaglutide and dipeptidyl peptidase-4 inhibitor sitagliptin therapy on serum levels of IGFBP-1, IGFBP-3, and IGFBP-rp1, and to analyze their associations with anthropometric variables and markers of carbohydrate and lipid metabolism. In this prospective study, we enrolled 34 patients with type 2 diabetes mellitus (T2DM) on metformin monotherapy and 31 age-, sex- and BMImatched controls. Among the patients, 18 received semaglutide, and 16 were treated with sitagliptin. Anthropometric and laboratory assessments were performed at baseline, 26 and 52 weeks. IGFBP levels were measured using ELISA. Both semaglutide and sitagliptin treatment significantly increased IGFBP-1 levels. IGFBP-3 levels were significantly decreased following sitagliptin therapy. No significant change in IGFBP-rp1 levels was observed with either treatment. Based on multiple regression analysis, the best predictors of IGFBP-1 were insulin and hsCRP, while the best predictor of IGFBP-3 was LDL-C level. Our findings suggest that semaglutide and sitagliptin may exert favorable effects on the GH/IGF-1 axis, potentially contributing to their beneficial metabolic outcomes in patients with T2DM.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
semaglutide
sitagliptin
insulin-like growth factor-binding protein
insulin
C-peptide
waist circumference
lipid parameters
C-reactive protein
type 2 diabetes mellitus
Megjelenés:International Journal Of Molecular Sciences. - 26 : 21 (2025), p. 1-14. -
További szerzők:Sztanek Ferenc (1982-) (orvos) Csiha Sára (1985-) (Biológus) Ratku Balázs (1985-) (mentőtiszt) Somodi Sándor (1977-) (belgyógyász) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Lőrincz Hajnalka (1986-) (biológus)
Pályázati támogatás:K142273
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM126140
035-os BibID:(Scopus)85213209914 (WoS)001384816200001
Első szerző:Hernyák Marcell (orvos)
Cím:Kallistatin as a Potential Marker of Therapeutic Response During Alpha-Lipoic Acid Treatment in Diabetic Patients with Sensorimotor Polyneuropathy / Hernyák Marcell, Tóth László Imre, Csiha Sára, Molnár Ágnes, Lőrincz Hajnalka, Paragh György, Harangi Mariann, Sztanek Ferenc
Dátum:2024
ISSN:1661-6596 1422-0067
Megjegyzések:Diabetic sensorimotor neuropathy (DSPN) is strongly associated with the extent of cellular oxidative stress and endothelial dysfunction in type 2 diabetes (T2DM). Alpha-lipoic acid (ALA) attenuates the progression of DSPN through its antioxidant and vasculoprotective effects. Kallistatin has antioxidant and anti-inflammatory properties. We aimed to evaluate changes in kallistatin levels and markers of endothelial dysfunction in patients with T2DM and DSPN following six months of treatment with 600 mg/day of ALA. A total of 54 patients with T2DM and DSPN and 24 control patients with T2DM but without neuropathy participated in this study. The serum concentrations of kallistatin, ICAM-1, VCAM-1, oxLDL, VEGF, ADMA, and TNF-alpha were measured by an ELISA. Peripheral sensory neuropathy was assessed with neuropathy symptom questionnaires and determination of the current perception threshold. After ALA treatment, the level of kallistatin significantly decreased, as well as the levels of TNF-alpha and ADMA. Changes in kallistatin levels were positively correlated with changes in oxLDL. The improvement in DSPN symptoms following ALA treatment showed a positive correlation with changes in kallistatin, VEGF, oxLDL, and ADMA levels. Based on our results, kallistatin could represent a potential new biomarker for assessing therapeutic response during ALA treatment in patients with DSPN.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
alpha-lipoic acid
diabetic sensorimotor neuropathy
endothelial dysfunction
kallistatin
type 2 diabetes
oxidative stress
Megjelenés:International Journal Of Molecular Sciences. - 25 : 24 (2024), p. 1-14. -
További szerzők:Tóth László (1997-) (orvos) Csiha Sára (1985-) (Biológus) Molnár Ágnes (1972-) (gyógytornász) Lőrincz Hajnalka (1986-) (biológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Sztanek Ferenc (1982-) (orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM121807
035-os BibID:(Scopus)85195883546 (WoS)001245410600001
Első szerző:Lőrincz Hajnalka (biológus)
Cím:Associations between Serum Kallistatin Levels and Markers of Glucose Homeostasis, Inflammation, and Lipoprotein Metabolism in Patients with Type 2 Diabetes and Nondiabetic Obesity / Hajnalka Lőrincz, Sára Csiha, Balázs Ratku, Sándor Somodi, Ferenc Sztanek, György Paragh, Mariann Harangi
Dátum:2024
Megjegyzések:Kallistatin is an endogenous serine proteinase inhibitor with various functions, including antioxidative, anti-inflammatory, and anti-atherosclerotic properties. To date, associations between kallistatin and lipoprotein subfractions are poorly investigated. In this study, we enrolled 62 obese patients with type 2 diabetes (T2D), 106 nondiabetic obese (NDO) subjects matched in gender, age, and body mass index, as well as 49 gender- and age-matched healthy, normal-weight controls. Serum kallistatin levels were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint? (Quantimetrix Corp., Redondo Beach, CA, USA) gel electrophoresis. Kallistatin concentrations were significantly higher in T2D patients compared to NDO and control groups. We found significant positive correlations between very-low-density lipoprotein (VLDL), small high-density lipoprotein (HDL) subfractions, glucose, hemoglobin A1c (HbA1c), betatrophin, and kallistatin, while negative correlations were detected between mean low-density lipoprotein (LDL) size, large and intermediate HDL subfractions, and kallistatin in the whole study population. The best predictor of kallistatin was HbA1c in T2D patients, high-sensitivity C-reactive protein (hsCRP) and betatrophin in NDO patients, and hsCRP in controls. Our results indicate that kallistatin expression might be induced by persistent hyperglycemia in T2D, while in nondiabetic subjects, its production might be associated with systemic inflammation. The correlation of kallistatin with lipid subfractions may suggest its putative role in atherogenesis.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
kallistatin
triglyceride
lipid subfractions
diabetes
obesity
betatrophin
Megjelenés:International Journal of Molecular Sciences. - 25 : 11 (2024), p. 1-12. -
További szerzők:Csiha Sára (1985-) (Biológus) Ratku Balázs (1985-) (mentőtiszt) Somodi Sándor (1977-) (belgyógyász) Sztanek Ferenc (1982-) (orvos) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:142273
OTKA
TKP2021-EGA-18
Egyéb
Eötvös Loránd Research Network (11003)
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM116322
035-os BibID:(WOS)001113721200001 (Scopus)85177740392
Első szerző:Lőrincz Hajnalka (biológus)
Cím:Gender-Dependent Associations between Serum Betatrophin Levels and Lipoprotein Subfractions in Diabetic and Nondiabetic Obese Patients / Hajnalka Lőrincz, Sára Csiha, Balázs Ratku, Sándor Somodi, Ferenc Sztanek, Ildikó Seres, György Paragh, Mariann Harangi
Dátum:2023
ISSN:1422-0067
Megjegyzések:Betatrophin, also known as angiopoietin-like protein 8 (ANGPTL8), mainly plays a role in lipid metabolism. To date, associations between betatrophin and lipoprotein subfractions are poorly investigated. For this study, 50 obese patients with type 2 diabetes (T2D) and 70 nondiabetic obese (NDO) subjects matched in gender, age, and body mass index (BMI) as well as 49 gender- and age-matched healthy, normal-weight controls were enrolled. Serum betatrophin levels were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint gel electrophoresis. Betatrophin concentrations were found to be significantly higher in the T2D and NDO groups compared to the controls in all subjects and in females, but not in males. We found significant positive correlations between triglyceride, very low density lipoprotein (VLDL), large LDL (low density lipoprotein), small LDL, high density lipoprotein (HDL) -6-10 subfractions, and betatrophin, while negative correlations were detected between betatrophin and IDL, mean LDL size, and HDL-1-5. Proportion of small HDL was the best predictor of betatrophin in all subjects. Small LDL and large HDL subfractions were found to be the best predictors in females, while in males, VLDL was found to be the best predictor of betatrophin. Our results underline the significance of serum betatrophin measurement in the cardiovascular risk assessment of obese patients with and without T2D, but gender differences might be taken into consideration.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
betatrophin
angiopoietin-like protein 8
triglyceride
lipoprotein subfractions
high-density lipoprotein
diabetes
obesity
Megjelenés:International Journal Of Molecular Sciences. - 24 : 22 (2023), p. 1-13. -
További szerzők:Csiha Sára (1985-) (Biológus) Ratku Balázs (1985-) (mentőtiszt) Somodi Sándor (1977-) (belgyógyász) Sztanek Ferenc (1982-) (orvos) Seres Ildikó (1954-) (biokémikus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:K142273
OTKA
PD146136
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM130785
035-os BibID:(WoS)001526345500001
Első szerző:Tóth László (orvos)
Cím:Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes : insights from a One-Year Follow-Up Study / Tóth László Imre, Harsányi Adrienn, Csiha Sára, Molnár Ágnes, Lőrincz Hajnalka, Nagy Attila Csaba, Paragh György, Harangi Mariann, Sztanek Ferenc
Dátum:2025
Megjegyzések:Recent studies have demonstrated the efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in enhancing glycemic control, regulating body weight, and modulating lipid metabolism. However, their effects on lipoprotein subfractions have not been clarified. The objective of this 52-week, single-center, randomized trial was to compare the effects of subcutaneous semaglutide administered once weekly and oral sitagliptin administered once daily on anthropometric measurements and lipoprotein subfractions measured by Lipoprint gelelectrophoresis in patients with type 2 diabetes mellitus (T2DM). A total of 34 obese individuals with T2DM were enrolled in the study and randomly assigned to receive semaglutide (n = 18) or sitagliptin (n = 16). Thirty-one age- and body weight-matched non-diabetic obese individuals served as controls. Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c, along with improvements in lipid parameters, including reductions in LDL cholesterol and non-HDL cholesterol levels, and redistribution of LDL and HDL subfractions toward a less atherogenic profile. Conversely, sitagliptin elicited modest glycemic improvements without substantial alterations in lipid composition. Multivariate regression analysis demonstrated that fluctuations in lipoprotein subfractions were not influenced by changes in BMI or HbA1c. These results support the pleiotropic metabolic benefits of semaglutide and its potential role in managing the cardiometabolic risk of T2DM.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
type 2 diabetes mellitus
semaglutide
sitagliptin
lipoprotein subfractions
GLP-1 receptor agonist
cardiometabolic risk
Megjelenés:International Journal of Molecular Sciences. - 26 : 13 (2025), p. 1-18. -
További szerzők:Harsányi Adrienn Csiha Sára (1985-) (Biológus) Molnár Ágnes Lőrincz Hajnalka (1986-) (biológus) Nagy Attila Csaba (1981-) (megelőző orvostan és népegészségtan szakorvos, epidemiológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Sztanek Ferenc (1982-) (orvos)
Pályázati támogatás:K142273
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.